CPC Biotech Partners with Multiply Labs for Robotic Automation in Cell Therapy Production
In an era where precision and automation are becoming increasingly vital in the biotechnology sector, CPC Biotech, a subsidiary of PSG and Dover (NYSE: DOV), has announced its collaboration with Multiply Labs. This partnership aims to significantly enhance robotic systems in cell therapy manufacturing processes, addressing a major bottleneck in the medical treatment of various diseases.
CPC Biotech specializes in producing essential components such as connectors, pumps, and flow sensors crucial for biopharmaceutical processing. Recognizing the pressing demand for quicker manufacturing solutions, the company is working to develop a revolutionary aseptic connector tailored for robotic use. According to Troy Ostreng, Senior Product Manager at CPC Biotech, the integration of automation and robotics is fundamental for accelerating patient access to advanced therapies.
Multiply Labs, headquartered in San Francisco, possesses a unique position in the market as a pioneer in utilizing robotics for the production of cell and gene therapy products. The company’s approach focuses on modular systems designed to alleviate manufacturing bottlenecks, reduce human contamination risks, and ultimately expand access to vital therapies for patients. Fred Parietti, Co-Founder and CEO of Multiply Labs, notes that traditional cell therapy operations rely entirely on manual processes. By leveraging robotic automation, they can achieve a level of scalability and affordability previously unattainable with manual methods.
A significant concern in cell therapy production is human involvement, which introduces contamination risks. Multiply Labs' innovative robotic systems operate in a contained sterile environment, eliminating the need for human operators to enter the production area. This paradigm shift necessitates effective management of system components entirely by robotic systems. The introduction of CPC Biotech’s new robot-optimized MicroCNX® Nano Series aseptic connectors, which feature a proprietary interface designed for robotic gripper manipulation, is set to revolutionize the industry.
One of the prevailing challenges in robotics is handling soft materials like tubing and bags. Troy Ostreng explains that incorporating a rigid connector at the end of the tubing provides robotic grippers with a stable and repeatable method of operation, thus facilitating the progress toward automation in cell therapy production. This advancement is highly significant in enabling robotics-based solutions that can transform the fundamentally manual workflows that have long dominated the field.
Both CPC Biotech and Multiply Labs emphasize the importance of maximizing production capacity while maintaining a compact operational footprint. The focus on reducing space requirements is critical for seamless integration within existing production environments. Parietti comments on the collaborative commitment to ease of use, modularity, and scalability. These attributes not only enhance operational efficiency but also foster confidence among cell therapy manufacturers in adopting automated methodologies.
“Reliability, repeatability, and simplification are essential components that will encourage cell therapy manufacturers to embrace automation with confidence,” stated Ostreng. The ultimate goal of this partnership is to ensure that therapies reach the patients who need them in a timely, efficient, and cost-effective manner.
This collaboration marks an important step in the ongoing transformation of biopharmaceutical manufacturing processes, as it leverages cutting-edge technology to streamline operations and improve patient outcomes. As CPC Biotech and Multiply Labs continue to drive innovation in this space, they pave the way for a future where cell therapies can be produced at scale, making advanced medical treatments more accessible to those in need.
For further insights into the capabilities and applications of MicroCNX connectors, visit CPC Biotech's official website.
CPC Biotech stands at the forefront of bioprocessing fluid management, providing a diverse portfolio of connectors, pumps, flow meters, and sensors essential for biopharmaceutical innovations. Their cutting-edge solutions enable the efficient production of biologics and therapeutics, ensuring optimal integrity and yield. As a part of Pump Solutions Group (PSG), a division within Dover Corporation, CPC Biotech is committed to advancing the field of medicine.
Multiply Labs is revolutionizing cell and gene therapy manufacturing by harnessing the power of robotics. Their modular automated solutions significantly enhance production efficiency while minimizing contamination risks, thus expanding access to critical therapies globally.
CPC Biotech specializes in producing essential components such as connectors, pumps, and flow sensors crucial for biopharmaceutical processing. Recognizing the pressing demand for quicker manufacturing solutions, the company is working to develop a revolutionary aseptic connector tailored for robotic use. According to Troy Ostreng, Senior Product Manager at CPC Biotech, the integration of automation and robotics is fundamental for accelerating patient access to advanced therapies.
Multiply Labs, headquartered in San Francisco, possesses a unique position in the market as a pioneer in utilizing robotics for the production of cell and gene therapy products. The company’s approach focuses on modular systems designed to alleviate manufacturing bottlenecks, reduce human contamination risks, and ultimately expand access to vital therapies for patients. Fred Parietti, Co-Founder and CEO of Multiply Labs, notes that traditional cell therapy operations rely entirely on manual processes. By leveraging robotic automation, they can achieve a level of scalability and affordability previously unattainable with manual methods.
A significant concern in cell therapy production is human involvement, which introduces contamination risks. Multiply Labs' innovative robotic systems operate in a contained sterile environment, eliminating the need for human operators to enter the production area. This paradigm shift necessitates effective management of system components entirely by robotic systems. The introduction of CPC Biotech’s new robot-optimized MicroCNX® Nano Series aseptic connectors, which feature a proprietary interface designed for robotic gripper manipulation, is set to revolutionize the industry.
One of the prevailing challenges in robotics is handling soft materials like tubing and bags. Troy Ostreng explains that incorporating a rigid connector at the end of the tubing provides robotic grippers with a stable and repeatable method of operation, thus facilitating the progress toward automation in cell therapy production. This advancement is highly significant in enabling robotics-based solutions that can transform the fundamentally manual workflows that have long dominated the field.
Both CPC Biotech and Multiply Labs emphasize the importance of maximizing production capacity while maintaining a compact operational footprint. The focus on reducing space requirements is critical for seamless integration within existing production environments. Parietti comments on the collaborative commitment to ease of use, modularity, and scalability. These attributes not only enhance operational efficiency but also foster confidence among cell therapy manufacturers in adopting automated methodologies.
“Reliability, repeatability, and simplification are essential components that will encourage cell therapy manufacturers to embrace automation with confidence,” stated Ostreng. The ultimate goal of this partnership is to ensure that therapies reach the patients who need them in a timely, efficient, and cost-effective manner.
This collaboration marks an important step in the ongoing transformation of biopharmaceutical manufacturing processes, as it leverages cutting-edge technology to streamline operations and improve patient outcomes. As CPC Biotech and Multiply Labs continue to drive innovation in this space, they pave the way for a future where cell therapies can be produced at scale, making advanced medical treatments more accessible to those in need.
For further insights into the capabilities and applications of MicroCNX connectors, visit CPC Biotech's official website.
About CPC Biotech
CPC Biotech stands at the forefront of bioprocessing fluid management, providing a diverse portfolio of connectors, pumps, flow meters, and sensors essential for biopharmaceutical innovations. Their cutting-edge solutions enable the efficient production of biologics and therapeutics, ensuring optimal integrity and yield. As a part of Pump Solutions Group (PSG), a division within Dover Corporation, CPC Biotech is committed to advancing the field of medicine.
About Multiply Labs
Multiply Labs is revolutionizing cell and gene therapy manufacturing by harnessing the power of robotics. Their modular automated solutions significantly enhance production efficiency while minimizing contamination risks, thus expanding access to critical therapies globally.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.